{"product_id":"skye-pestle-analysis","title":"(SKYE) Skye Bioscience, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Skye Bioscience, Inc. PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces shaping the company and why they matter for strategy and investment. This page shows a real preview\/sample of the analysis so you can judge style and depth; purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA IND oversight for 1 lead asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience’s SBI-100 sits under FDA IND control, so the agency’s 30-day review clock, safety reporting rules, and endpoint checks shape trial pace. Any protocol tweak, dose step-up, or safety signal needs FDA alignment, which can slow a first-in-human ophthalmic program. Political support for faster biotech review helps, but oversight stays strict because one lead asset means less room for error.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. federal cannabis policy uncertainty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience's cannabinoid research sits under U.S. federal cannabis uncertainty: cannabis stayed Schedule I under the Controlled Substances Act, even after HHS recommended Schedule III in 2023. That gap can affect licensing, sourcing, and FDA-facing studies, so policy shifts can move project timelines fast. Even non-psychoactive programs can draw extra scrutiny because regulators still look at source chemistry and enforcement priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCalifornia biotech hub in San Diego\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. is based in San Diego, a biotech hub with 1,300+ life-science companies, strong university pipelines, and dense CRO, CDMO, and lab-service access. Local political support for life sciences can ease hiring and partnering, but California’s rules stay tough; the state’s 8.84% corporate tax and stricter labor, environmental, and reporting standards raise compliance costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic research funding for eye disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic funding keeps ophthalmology research active: the U.S. National Eye Institute’s FY2024 budget was about $852 million, supporting work on glaucoma, dry eye, and retinal disease. That matters for Skye Bioscience, Inc. because these markets still have high unmet need, so government-backed science can raise trial quality and disease awareness. Policy support for vision health also makes it easier to build research partnerships and recruit centers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNEI FY2024 budget: about $852 million.\u003c\/li\u003e\n\u003cli\u003eSupports glaucoma, dry eye, retinal research.\u003c\/li\u003e\n\u003cli\u003eRaises awareness and collaboration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealthcare access and reimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlaucoma and ocular hypertension drugs must clear payer rules, not just clinical trials. Medicare covered about 66 million people in 2025, so Part D access and formulary placement can decide uptake fast, especially for a small biopharma like Skye Bioscience, Inc..\u003c\/p\u003e\n\u003cp\u003ePolicy matters too: the 2025 Medicare Part D out-of-pocket cap is $2,000, which can change demand and plan behavior for chronic eye therapies. Medicaid and state prescription rules still shape whether approved drugs get used at scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage can drive launch speed.\u003c\/li\u003e\n\u003cli\u003ePricing pressure hits small biopharma hard.\u003c\/li\u003e\n\u003cli\u003eAccess can matter as much as efficacy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkye Bioscience Faces FDA, Cannabis, and California Cost Headwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. faces FDA IND control, so trial timing depends on the 30-day review clock, safety reporting, and any protocol change approvals. U.S. cannabis policy still adds risk because cannabis remains Schedule I, even after HHS recommended Schedule III in 2023. California’s 8.84% corporate tax and strict state rules also lift compliance costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA IND\u003c\/td\u003e\n\u003ctd\u003e30-day review clock\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFederal cannabis\u003c\/td\u003e\n\u003ctd\u003eSchedule I\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCalifornia tax\u003c\/td\u003e\n\u003ctd\u003e8.84%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Skye Bioscience, Inc.’s external environment across Political, Economic, Social, Technological, Environmental, and Legal factors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Skye Bioscience PESTLE snapshot that cuts through noise and speeds up risk review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources for Skye Bioscience to validate market sizing, pricing, and competitive assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 pipeline programs, 1 clinical and 1 preclinical\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience’s pipeline is narrow, with SBI-100 in clinic and SBI-200 in preclinical work. That focus can drive sharp upside if one readout lands well, but it also makes the Company highly sensitive to timing and cash burn. With only two shots on goal, any delay in trial data can raise financing risk fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh clinical-stage cash demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiopharma programs can spend $3 million to $10 million or more just to reach and run Phase I, before any revenue starts, and SBI-100 adds near-term burn through manufacturing, toxicology, and FDA work. In 2025, small-cap biotech funding stayed tight, so Skye Bioscience, Inc.'s access to capital is a key economic driver for trial speed and survival.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall-cap biotech financing conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. relies on equity markets for runway, and the Fed’s policy rate stayed in a 4.25%-4.50% range in late 2025, keeping capital expensive. In 2025, biotech IPO and follow-on windows stayed selective, so clinical-stage names faced thinner demand and weaker pricing. That can force more dilution per dollar raised and shorten the time Skye Bioscience, Inc. can fund trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLarge unmet market in glaucoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlaucoma is a large chronic market: about 76 million people were living with it in 2020, and cases are projected to reach 111.8 million by 2040. Because treatment is long-term, even a small share of this patient pool can generate meaningful revenue if Skye Bioscience, Inc. offers clear efficacy or tolerability gains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e76 million global patients in 2020\u003c\/li\u003e\n\u003cli\u003e111.8 million projected by 2040\u003c\/li\u003e\n\u003cli\u003eChronic use supports recurring sales\u003c\/li\u003e\n\u003cli\u003eLarge TAM can justify R\u0026amp;D spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline value depends on binary data events\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkye Bioscience, Inc.'s value can swing sharply on SBI-100 data, because clinical biotech prices often react to one safety or efficacy readout. That makes upside large if results are strong, but it also raises volatility and can tighten access to capital if data disappoints. In biotech, one binary event can re-rate enterprise value fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne trial readout can move value fast.\u003c\/li\u003e\n\u003cli\u003eStrong SBI-100 data can lift valuation.\u003c\/li\u003e\n\u003cli\u003eWeak data can hurt funding access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Rates Raise the Stakes for Skye Bioscience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. depends on equity markets, and late-2025 rates at 4.25%-4.50% kept capital costly for small biotech. That can mean more dilution and shorter runway.\u003c\/p\u003e\n\u003cp\u003eIts narrow pipeline makes funding gaps more dangerous, because SBI-100 data can move valuation fast while SBI-200 is still preclinical. One weak readout can tighten access to cash.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed rate\u003c\/td\u003e\n\u003ctd\u003e4.25%-4.50% in late 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlaucoma patients\u003c\/td\u003e\n\u003ctd\u003e76 million in 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected cases\u003c\/td\u003e\n\u003ctd\u003e111.8 million by 2040\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eSkye Bioscience, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Skye Bioscience, Inc. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategy or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAge-related rise in glaucoma risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlaucoma risk rises sharply with age, so aging populations expand the addressable patient pool for Skye Bioscience, Inc. Around 80 million people globally live with glaucoma, and cases are projected to reach 111.8 million by 2040. Older adults also need long-term intraocular pressure control and monitoring, supporting demand for chronic ophthalmic therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMillions of patients with chronic eye disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlaucoma affects about 80 million people worldwide, and diabetic retinopathy about 103 million, while dry eye, uveitis, and macular degeneration add even more chronic cases. These conditions drive repeated specialist visits and long treatment cycles, so patients often choose therapies that are easier to use and better tolerated. For Skye Bioscience, Inc., adherence and convenience matter as much as efficacy because social behavior can determine whether patients stay on therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreference for non-surgical options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn the U.S., glaucoma affects about 3 million people, and many eye patients still prefer drops or other non-surgical care over invasive procedures. A well-tolerated topical therapy can fit routine ophthalmology visits, which may improve acceptance and adherence. For Skye Bioscience, Inc., that social bias supports drug candidates designed to be simple to use and easy to prescribe.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic perception of cannabinoids\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic view of cannabinoids is still split: medical use is gaining trust, but cannabis stigma can slow hiring, weaken investor trust, and confuse patients. For Skye Bioscience, Inc., clear medical framing matters because mainstream eye care will judge the science, not the plant source.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStigma can raise recruitment friction.\u003c\/li\u003e\n\u003cli\u003eMedical labeling improves patient trust.\u003c\/li\u003e\n\u003cli\u003eClear data helps investor confidence.\u003c\/li\u003e\n\u003cli\u003eEye-care adoption needs clean positioning.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNeed for earlier screening and diagnosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlaucoma can progress for years before symptoms, so earlier screening drives earlier treatment. The WHO says glaucoma affects over 80 million people globally and is a leading cause of irreversible blindness, which makes awareness and routine eye exams a key demand driver for Skye Bioscience, Inc. If patients and clinicians act sooner, more people enter therapy before major vision loss.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSilent progression delays diagnosis\u003c\/li\u003e\n\u003cli\u003eAwareness lifts screening rates\u003c\/li\u003e\n\u003cli\u003eEarlier care expands treatment use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlaucoma’s rise boosts demand for simple, non-surgical eye care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOlder adults drive demand: glaucoma affects about 80 million people worldwide, and cases may reach 111.8 million by 2040. In the U.S., about 3 million people have glaucoma, so routine screening and long-term care matter. Patients still prefer simple, non-surgical eye care, which helps Skye Bioscience, Inc. therapies that are easy to use and well tolerated.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSocial factor\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAging\u003c\/td\u003e\n\u003ctd\u003e80M global cases\u003c\/td\u003e\n\u003ctd\u003eMore chronic therapy use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAwareness\u003c\/td\u003e\n\u003ctd\u003e111.8M by 2040\u003c\/td\u003e\n\u003ctd\u003eEarlier screening helps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSBI-100 in Phase I clinical testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience's SBI-100 is already in Phase I, the key first-human milestone in drug development. Phase I studies test safety, tolerability, and dose, and the readout decides if the program can move into later trials. Because early studies usually involve only small patient groups, each result carries outsized weight for Skye's platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSBI-200 in preclinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSBI-200 is still in preclinical development, so its value depends on strong discovery data, clean nonclinical results, and proof of biological activity before any human dosing can start.\u003c\/p\u003e\n\u003cp\u003eThat stage must also show a viable safety profile, since no clinical efficacy data exist yet; for Skye Bioscience, Inc., this is the key next value driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOphthalmic delivery technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOphthalmic delivery is a key tech barrier for Skye Bioscience, Inc. because the eye blocks drug entry; topical bioavailability is often under 5%, and tears can wash drops out in minutes. So penetration and residence time matter as much as the molecule itself. Better delivery can lift efficacy and tolerability at the same time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCannabinoid receptor biology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkye Bioscience’s cannabinoid-receptor platform is technologically different from standard glaucoma drops because it targets receptor biology, not just eye-pressure symptoms. That makes proof of receptor activity and downstream intraocular pressure lowering the key scientific test.\u003c\/p\u003e\n\u003cp\u003eIn glaucoma, a 1 mmHg drop in intraocular pressure can matter, so Skye’s moat depends on showing that CB1-linked mechanisms move pressure or disease biology in a measurable way. Without that link, the platform’s differentiation stays theoretical.\u003c\/p\u003e\n\u003cp\u003eThis makes cannabinoid pharmacology central to Skye Bioscience, Inc.’s value: if receptor selectivity, dosing, and safety hold up in human data, the company can stand apart from prostaglandin, beta-blocker, and carbonic anhydrase inhibitor treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eImaging and clinical endpoint tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOphthalmology trials hinge on hard endpoints like intraocular pressure and retinal imaging, so sharper tools matter. In small studies, better OCT and image grading can lift signal detection and cut noise, which is key for Skye Bioscience, Inc.'s low-patient programs. The FDA cleared more than 50 ophthalmic devices in recent years, showing how fast measurement tech is improving.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore precise imaging reduces trial noise.\u003c\/li\u003e\n\u003cli\u003eBetter endpoints strengthen go or no-go calls.\u003c\/li\u003e\n\u003cli\u003eSmall studies need cleaner signals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkye Bioscience Faces Key Clinical and Delivery Hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. depends on proving its tech in two weak spots: first, SBI-100 must clear Phase I safety and dose tests; second, SBI-200 still has to earn preclinical proof before any human study. Its eye-drop delivery also faces a hard barrier, since topical bioavailability is often under 5%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTech factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical stage\u003c\/td\u003e\n\u003ctd\u003eSBI-100 Phase I; SBI-200 preclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEye delivery\u003c\/td\u003e\n\u003ctd\u003eTopical bioavailability under 5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget effect\u003c\/td\u003e\n\u003ctd\u003e1 mmHg IOP change can matter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA clinical trial compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. must run clinical work under FDA IND rules, with informed consent and safety reporting. Serious adverse events need FDA follow-up in 7 or 15 days, so Phase I data are watched closely for protocol drift and toxicity. Any deviation can force a clinical hold, add review, and slow cash use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eControlled substance and cannabinoid rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. faces strict controlled-substance and cannabinoid rules because federal law still treats cannabis as Schedule I, even as 38 states plus D.C. allow medical use and 24 states allow adult use. That split can affect sourcing, importation, lab handling, and trial logistics. Clear rules are key to keep development scalable and avoid delays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent protection for 2 assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience’s value depends on strong patents around composition, formulation, and use claims. Protection for SBI-100 and SBI-200 can block direct rivals for up to about 20 years from filing, which supports pricing power and partner interest.\u003c\/p\u003e\n\u003cp\u003eIf IP coverage is weak, licensing terms usually get worse, and the 2 assets become easier to copy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSEC reporting as a public company\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. must keep filing timely 10-K, 10-Q, and 8-K reports under U.S. securities law, so clinical updates, financing moves, and risk changes have to be disclosed fast and consistently. That transparency helps investors, but any missing or uneven disclosure can trigger SEC scrutiny and shareholder suits.\u003c\/p\u003e\n\u003cp\u003eFor a small biotech with one lead asset, even a single trial update can move the stock hard, so disclosure quality matters as much as the data itself.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTimely SEC filings are mandatory.\u003c\/li\u003e\n\u003cli\u003eClinical news must be consistent.\u003c\/li\u003e\n\u003cli\u003eFinancing events need full disclosure.\u003c\/li\u003e\n\u003cli\u003eIncomplete disclosure raises litigation risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProduct liability and trial liability risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHuman testing and later commercialization both create product liability and trial liability risk for Skye Bioscience, Inc. if safety signals appear. Ophthalmic products face strict FDA labeling, warning, and quality rules, and even one failure can trigger recalls, claims, and cash-heavy defense costs. For a small company, that risk matters more because litigation can absorb a large share of limited capital.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHuman trials can trigger safety claims.\u003c\/li\u003e\n\u003cli\u003eOphthalmic labeling must be exact.\u003c\/li\u003e\n\u003cli\u003eSmall cash reserves raise damage risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkye Bioscience’s Legal Risk Map: FDA Rules, Cannabis Law, Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. faces FDA IND, consent, and safety-reporting rules, where serious adverse events need 7- or 15-day follow-up and can trigger holds. Its cannabinoid work also sits in a split U.S. legal setting: cannabis is still Schedule I federally, while 38 states plus D.C. allow medical use and 24 states allow adult use. Strong patents and clean SEC filings are critical to protect SBI-100 and SBI-200 and limit litigation risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA safety reporting\u003c\/td\u003e\n\u003ctd\u003e7\/15-day SAE follow-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. cannabis law\u003c\/td\u003e\n\u003ctd\u003e38 states + D.C. medical; 24 adult-use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent term\u003c\/td\u003e\n\u003ctd\u003eUp to ~20 years from filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEC disclosure\u003c\/td\u003e\n\u003ctd\u003e10-K, 10-Q, 8-K required\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSan Diego California operating base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience's San Diego base puts it under California's strict environmental rules on waste, emissions, and lab operations, so day-to-day compliance matters as much as drug development. The state also keeps tightening oversight: California has about 4% of the U.S. population but often drives tougher facility standards than many other states. That raises operating cost and reporting needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory waste and chemical disposal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiopharma labs generate solvent, biological, and single-use consumable waste, and U.S. hazardous-waste rules can turn small process changes into real cost swings. Under EPA limits, 100 to 1,000 kg of hazardous waste a month can place a site in small quantity generator status, while 1,000 kg or more can trigger large quantity rules, so disposal discipline protects both margin and compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy use in research facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc.'s drug discovery and clinical support work depends on cold storage, HVAC, and specialized lab gear, so power is a real operating cost even for a small biotech. Life science labs can use 3 to 10 times more energy than standard office space, which makes facility choice and vendor contracts important. Higher electricity prices and ESG targets can also shape where Skye Bioscience, Inc. runs work and stores materials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClimate-related supply chain disruption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClimate events can delay research materials, cold-chain shipments, and clinical supplies, and even a short temperature excursion can force material loss or re-testing. For Skye Bioscience, Inc., West Coast port delays and global freight volatility can push sample and trial-material timelines by days or weeks, raising cost and protocol risk. Environmental resilience matters in both shipping and site operations, not just facilities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLower-emission expectations in life sciences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiopharma buyers now screen suppliers for Scope 1-3 emissions, waste, and sourcing; CDP said more than 23,000 companies disclosed climate data in 2024, so the bar is rising. For pre-revenue firms like Skye Bioscience, Inc., missing environmental policies can hurt vendor approval, reputation, and future partnership talks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDisclose emissions and sourcing early\u003c\/li\u003e\n\u003cli\u003eExpect supplier ESG checks\u003c\/li\u003e\n\u003cli\u003ePolicy gaps can block partnerships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkye Bioscience Faces Rising Lab Compliance and Climate Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSkye Bioscience, Inc. faces California’s tighter waste, emissions, and lab rules, so compliance costs can move with facility use. Biopharma labs also face hazardous-waste thresholds: 100-1,000 kg\/month can mean small-quantity status, and 1,000 kg+ can trigger large-quantity rules. Energy use and cold-chain risk matter too, since life science labs can use 3-10x office energy. CDP said 23,000+ firms disclosed climate data in 2024, so supplier scrutiny is rising.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHazardous waste\u003c\/td\u003e\n\u003ctd\u003e100-1,000 kg\/month SQG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHazardous waste\u003c\/td\u003e\n\u003ctd\u003e1,000 kg+ LQG\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab energy use\u003c\/td\u003e\n\u003ctd\u003e3-10x office space\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClimate disclosure\u003c\/td\u003e\n\u003ctd\u003e23,000+ CDP reporters, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235017990409,"sku":"skye-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/skye-pestle-analysis.webp?v=1785731704","url":"https:\/\/dcfanalyst.com\/products\/skye-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}